Everything below concerns aggregation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-25. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Sodium is found in many different minerals, of which the most common is ordinary salt (sodium chloride), which occurs in vast quantities dissolved in seawater. Other solid deposits include halite, amphibole, cryolite, nitratine, and zeolite. Many of these solid deposits occur as a result of ancient seas evaporating, which still occurs now in places such as Utah's Great Salt Lake and the Dead Sea. Despite their near-equal abundance in Earth's crust, sodium is far more common than potassium in the ocean, both because potassium's larger size makes its salts less soluble, and because potassium is bound by silicates in soil and what potassium leaches is absorbed far more readily by plant life than sodium. Despite its chemical similarity, lithium typically does not occur together with sodium or potassium due to its smaller size. Due to its relatively low reactivity, it can be found in seawater in large amounts; it is estimated that lithium concentration in seawater is approximately 0.14 to 0.25 parts per million (ppm) or 25 micromolar. Its diagonal relationship with magnesium often allows it to replace magnesium in ferromagnesium minerals, where its crustal concentration is about 18 ppm, comparable to that of gallium and niobium. Commercially, the most important lithium mineral is spodumene, which occurs in large deposits worldwide. Rubidium is approximately as abundant as zinc and more abundant than copper. It occurs naturally in the minerals leucite, pollucite, carnallite, zinnwaldite, and lepidolite, although none of these contain only rubidium and no other alkali metals.
Legislative measures to limit the sale of hydrogen peroxide products to concentrations of 12% or lower for the general public have been made in the European Union. A key disadvantage is the high susceptibility of TATP to accidental detonation, causing injuries and deaths among illegal bomb-makers, which has led to TATP being referred to as the "Mother of Satan". TATP was found in the accidental explosion that preceded the 2017 terrorist attacks in Barcelona and surrounding areas. Large-scale TATP synthesis is often betrayed by excessive bleach-like or fruity smells. The smell can even penetrate into clothes and hair in amounts that are quite noticeable; this was reported in the 2016 Brussels bombings. TATP was found in the bombs used in the 2026 New York City bombing attempt outside of Gracie Mansion on the Upper East Side of Manhattan, New York, but the devices did not explode.
The various temperature rests favour the activity of different enzymes, depending on the type and modification level of the malt and the brewer's intentions. Of particular importance are α-amylase and β-amylase, which hydrolyse starch to produce dextrins and fermentable sugars such as maltose. A traditional step mash may include a β-glucanase and protein rest around 45 °C (113 °F), a β-amylase rest around 62 °C (144 °F), and an α-amylase rest around 70 °C (158 °F). With modern well-modified malts, the lower-temperature rests are often omitted, and mashing may begin directly at temperatures where the amylases are more active. β-glucanases break down β-glucans in the mash, while proteolytic enzymes break down proteins into smaller peptides and amino acids. In modern brewing, commercial β-glucanase preparations may also be added to the mash. During saccharification, a mash rest of around 65–71 °C (149–160 °F) is commonly used. Lower temperatures within this range favour β-amylase activity and generally produce a more fermentable wort, while higher temperatures favour α-amylase activity and generally produce a less fermentable wort containing more dextrins. Mash temperature, duration and pH therefore influence the carbohydrate composition and fermentability of the resulting wort.
Four drugs from the class of direct Xa inhibitors are marketed worldwide. Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. The second one was apixaban (Eliquis), approved in Europe in 2011 and in the United States in 2012. The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. Betrixaban (Bevyxxa) was approved in the US in 2017.
Sources: en.wikipedia.org
=== Biogeography and environmental gradients === Ectomycorrhizal fungi are found throughout boreal, temperate and tropical ecosystems, primarily among the dominant woody-plant-producing families. Many of the fungal families common in temperate forests (e.g. Russulaceae, Boletaceae, Thelephoraceae) are also widespread in the Southern Hemisphere and tropical dipterocarp forests: although the plant families are quite different in temperate and tropical forests, the ectomycorrhizal fungi are fairly similar. The types of EcM fungi are affected by soil types both in the field and in the lab. For most types of plants and animals, species diversity increases towards the equator. This is called the latitudinal gradient of diversity (LGD). In contrast, there is evidence that EcM fungi may be at maximum diversity in the temperate zone. If this is the case, it might be explained by one or more of the following hypotheses: 1) EcM fungi may have evolved at higher latitudes with Pinaceae hosts, and be less able to compete in tropical climates; 2) the plants EcMs use as hosts might be more diverse in temperate conditions, and the structure of the soil in temperate regions may allow for higher niche differentiation and species accumulation; and 3) tropical EcM hosts are spread out more sparsely in small isolated forest islands that may reduce the population sizes and diversity of EcM fungi.
Celia. A White witch, Nathan's former mentor with whom he was sent to live. She abused and locked him in a cage in the first book and Nathan has despised her ever since. Soul O'Brien. The leader of the Council of White Witches and Annalise's uncle. Mr. Wallend. An evil White witch who works for Soul and carries out gruesome experiments on Black witches. Annalise O'Brien. A White witch, some months older than Nathan. She is Nathan's initial primary love interest. She also ran from her cruel family upon learning of their tolerance for the White witches' cruelty. Jessica Byrn. Nathan's eldest half-sister who hates him, and a Hunter.
== External links == "Ghrelin Receptor". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2015-07-11. Retrieved 2007-10-25. growth+hormone+secretagogue+receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Ghrelin Archived 2008-05-12 at the Wayback Machine at Colorado State University This article incorporates text from the United States National Library of Medicine, which is in the public domain.
=== Separation of powers of the federal and state governments === The federation agreement (Perjanjian Persekutuan) set the powers of the federal and state governments. Financial matters must be handled by the respective states. The Sultan was given full power on religious issues and Malay customs. Foreign policy and defence continued to be administered by the British government. The federation agreement was made the Constitution of the Federation of Malaya and officially declared on 1 February 1948.
=== Issues with theories === No single type of theory is satisfactory on its own; social cognition theories poorly address autism's rigid and repetitive behaviors, while most of the nonsocial theories have difficulty explaining autism's social impairment and communication difficulties. A combined theory based on multiple deficits may prove to be more useful.
Sources: en.wikipedia.org
Terry Peter Gallagher as Axel Zufo, a fossil fuels billionaire Billy Eichner as Waylen Lemming, a crypto billionaire David Pittu as Ronan Wylde, a banking billionaire Julie Halston as Kitty Munson, a multinational retail billionaire Matthew Laureano as Nate, a victim who is tortured and killed by the Assassin and Jeremy Rev Yolanda as Clara Gardner, a transgender scientist and Mike's best friend Lux Pascal as Clara after the transformation Laura Dreyfuss as Jennifer King Robert Harrington as Jefferson, Byron's bodyguard Kelli O'Hara as Juliana Williams, Meyer's wife Hazel Graye as Juliana after the transformation Kaylee Halko as Joey, the teenage daughter of Meyer and Juliana who has progeria Augusta Liv as Joey after the transformation Kevin Cahoon as Tiger "Tig" Forst, one of Byron and Franny's sons Ray Nicholson as Tig after the transformation Eric Petersen as Gunther Forst, one of Byron and Franny's sons Brandon Gillard as Gunther after the transformation Anthony Rapp as a Scientist who worked for the space colonization division of Byron's corporation Emma Halleen as Bella Grant, a school student who becomes fixated on the "Beauty" Annabelle Wachtel as Ruthie, Bella's best friend who is lamenting a failed nose job Paige McGarvin as Ruthie after the transformation Maria Dizzia as Marcy Grant, Bella's mother Daniel Stewart Sherman as Bella's father Carson Rowland as Conor, an employee of Byron's corporation who administers doses of the "Beauty" Ethan Eisenstein as Conor before the transformation Red Concepcion as Sir Ma'am, a social media influencer Sky Kawai as Sir Ma'am after the transformation
Chemists use the study of intramolecular and intermolecular non-covalent bonding/interactions in molecules to evaluate reactivity. Such interactions include, but are not limited to, hydrogen bonding, electrostatic interactions between charged molecules, dipole-dipole interactions, polar-π and cation-π interactions, π-stacking, donor-acceptor chemistry, and halogen bonding. In addition, the hydrophobic effect—the association of organic compounds in water—is an electrostatic, non-covalent interaction of interest to chemists. The precise physical origin of the hydrophobic effect originates from many complex interactions, but it is believed to be the most important component of biomolecular recognition in water. For example, researchers elucidated the structural basis for folic acid recognition by folate acid receptor proteins. The strong interaction between folic acid and folate receptor was attributed to both hydrogen bonds and hydrophobic interactions. The study of non-covalent interactions is also used to study binding and cooperativity in supramolecular assemblies and macrocyclic compounds such as crown ethers and cryptands, which can act as hosts to guest molecules.
However, according to Ken Gillman, the dose of cyproheptadine recommended to ensure blockade of the 5-HT2 receptors for serotonin syndrome is 20 to 30 mg based on the PET findings. Blockade of the serotonin 5-HT2B receptor may be specifically involved in the antimigraine effects of cyproheptadine. The drug has been found to prevent pergolide-induced cardiac valvulopathy, which can be assumed to be due to its serotonin 5-HT2B receptor antagonism. Cyproheptadine has been found to partially block the discriminative stimulus properties of the psychedelic drug LSD in rodent drug discrimination tests. It also antagonizes the discriminative stimulus properties of various other serotonergic agents, like 5-MeO-DMT, quipazine, fenfluramine, and 5-hydroxytryptophan (5-HTP). In addition, cyproheptadine blocks the head-twitch response induced by LSD, 5-MeO-DMT, quipazine, and 5-HTP in rodents. However, high doses of cyproheptadine have been reported to produce partial LSD-like discriminative stimulus effects in rodents. Possibly in relation to this, cyproheptadine has been said to sometimes be associated with hallucinations in humans. As an alternative possibility however, the partial generalization may instead be related to the highly non-selective nature of cyproheptadine and interactions at other neurotransmitter sites.
27 March – Humza Yousaf is elected as the Leader of the Scottish National Party and subsequently, First Minister of Scotland. He is the youngest holder of the position in history at just 37 years of age upon entry to office, the first from an ethnic minority background, the first Muslim to hold the office and the first First Minister with facial hair. 28 March Humza Yousaf is confirmed as Scotland's First Minister by a vote in the Scottish Parliament. Kate Forbes is to leave the Scottish Government after turning down a position in the Yousaf ministry. 29 March – Humza Yousaf is sworn in as Scotland's First Minister at Edinburgh's Court of Session and begins naming his Cabinet. 30 March The Parliamentary Standards Committee recommends that former Scottish National Party MP Margaret Ferrier be suspended from the House of Commons for 30 days for breaching COVID-19 regulations in September 2020 when she took a train home from London following a positive COVID test. Humza Yousaf attends his first session of First Minister's Questions since his election as First Minister. The session is interrupted on several occasions by climate change protestors, forcing the Presiding Officer of the Scottish Parliament to clear the gallery of visitors.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.